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Abstract  
Immune Reconstitution Inflammatory Syndromes (IRIS) are exaggerated pathological inflammatory reactions occurring after initiation of highly 
active antiretroviral therapy (HAART) due to exuberant immune responses to occult or apparent opportunistic infections or cancers. In view of 
paucity of studies from Nigeria, we report 3 cases of IRIS presenting as disseminated infections in HIV-1 infected patients initiating HAART. The 
first case was a previously healthy female who developed disseminated tuberculosis after 4 weeks of regular HAART. Her HAART regimen was 
continued and she improved after commencement of anti-tuberculosis drugs, with evidence of progressive increase in CD4 cell count. The second 
case was a HAART-experienced female who stopped her drugs for 4months. Two months after recommencement of her previous HAART regimen, 
she developed features of disseminated herpes zoster infection, despite evidence of decrease in viral load by 95%. HAART was continued and she 
recovered completely after receiving valaciclovir tablets and antibiotics. The third patient was a female student who was commenced HAART on 
account of chronic cough and weight loss. Three months after regular HAART, she developed features of disseminated Kaposi’s sarcoma involving 
the skin, oropharynx and lungs, despite evidence of 42% increase in CD4 cell count. Unfortunately, she rapidly deteriorated and died during the 
course of management. Clinicians should be alert to the possibility of IRIS in HIV-infected patients initiated or re-initiated on HAART. There is need 
for future prospective studies determining risk factors for IRIS in HIV-infected patients from Nigeria.  
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Introduction 
 
Highly active antiretroviral therapy (HAART) suppresses HIV-replication and restores immune function ultimately improving the quality of life and 
prolonging survival of HIV-infected patients. Unfortunately, during HAART-induced restoration of immune function, some patients may experience 
an exaggerated pathological inflammatory response termed immune reconstitution inflammatory syndrome (IRIS)[1]. IRIS has been reported in 
10-40% of patients initiating HAART [2,3]. Although IRIS may not significantly portend poor long term prognosis [4], it increases the rate of 
hospitalisation thereby increasing the cost of care of affected individuals [2].  
  
In view of prevailing high HIV prevalence and high rate of new infections, as well as increasing access to HAART, many HIV-infected individuals in 
sub-Saharan Africa are at a risk of developing IRIS on initiating HAART. However, there is still paucity of studies on IRIS from countries such as 
Nigeria where an estimated 4500 new HIV infections occur yearly and more than 500 000 HIV-infected patients are expected to initiate HAART [5]. 
For the first time from Nigeria, we report 3 peculiar cases of disseminated infections due to IRIS in HIV-1 infected patients receiving HAART at 
Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State.  
  
  
Case report 
  
A 37-year old housewife was commenced HAART-(Emtricitabine/Tenofovir/Nevirapine) after 1year progressive weight loss and recurrent diarrhoea, 
without fever or cough or radiological features of pulmonary tuberculosis. Four weeks after regular HAART, she presented with non-productive 
cough, breathlessness, fever and progressive painful bilateral inflammatory cervical adenopathies. Chest examination was normal. A repeat chest 
X-ray however, revealed features suggestive of perihilar adenopathies. Histology of biopsied cervical node confirmed tuberculosis-(TB) granuloma. 
A diagnosis of disseminated TB-(lungs and nodes) secondary to IRIS was made. A full blood count revealed a packed cell volume of 28% and total 
white cell count of 2.9 X 10
³/l, with predominant neutrophils (52%) and lymphocytes (40%). Renal and liver function tests were normal. Standard 
combination anti-TB drugs by DOTS were commenced along with tablets prednisolone 40mg daily (tapered). Her HAART regimen was continued 
but Nevirapine was switched for Efavirenz to avoid drug interactions. All symptoms gradually resolved and by the 3rd month on HAART, her CD4 
cell count had increased from 15cells/ul to 163cells/ul.  
  
Case 2  
  
A 47-years old previously healthy HIV-1 infected female was recommenced HAART-(Emtricitabine/Tenofovir/Nevirapine) after four months of non-
compliance. Two months after re-initiation of regular HAART, she developed high grade fever, cough and painful vesicobullous eruptions extending 
from  the  abdomen  to  the  buttocks  within  the  T11-  L2  dermatomes  (Figure  1).  Cough  was  productive  of  mucoid  sputum  with  associated 
breathlessness at rest and scattered coarse crepitations in both lung fields. On HAART, her HIV viral load had dropped from 27873 copies/ml to 
1267 copies/ml but the CD4 cell count changed slightly (266 to 267cells/ul). Full blood count revealed a packed cell volume of 30% and total white 
cell count of 4.8 X 10
³/L, with predominant neutrophils (58%) and lymphocytes (35%). Renal function tests were normal. Chest-X-ray revealed 
bilateral interstitial opacities. Sputum analysis for bacteria including mycobacteria was negative A clinical diagnosis of disseminated herpes zoster 
infection (skin and lungs) secondary to IRIS was made. Her previous HAART regimen was continued and tablets valaciclovir 1g bd, intravenous 
ceftriazone 1g daily and analgesics - Diclofenac potassium 50mg bd were commenced, along with dressing of ulcers. She recovered and continues 
to do well on follow up.  
  
Case 3  
  
A 19-years old HIV-1 infected female student was commenced HAART-(Tenofovir/Emtricitabine/Efavirenz) and empirical anti-TB drugs on account 
of eight months history of recurrent fever and weight loss, and one month history of cough with haemopytsis. After three months on regular 
HAART and three weeks on anti-TB drugs, she developed papulonodular discoloured skin lesions associated with oedema (Figure 2), painful 
generalised lymphadenopathies and worsening cough and breathlessness. On chest examination she was severely breathless with wide spread 
coarse crepitations in both lung fields. Other systemic examinations were not remarkable. While on HAART her CD4 cell count had increased from 
172cells/ul  to  297cells/ul.  At  presentation,  her  packed  cell  volume  was  32%  and  total  white  cell  count  was  4.5  X  10
³/L,  with  predominant 
neutrophils (63%) and lymphocytes (26.4%). Sputum microscopy and cytology were negative for AFB and malignant cells respectively. Chest X-ray 
showed diffuse bilateral alveolar opacities with obliteration of cardiac borders. Skin biopsy confirmed Kaposi’s sarcoma but histology of nodal fine 
needle aspirates revealed non-specific chronic inflammation. A diagnosis of disseminated Kaposi’s sarcoma (Skin, nodes, lungs) secondary to IRIS 
was made. Her previous HAART regimen was continued and anti-tuberculosis drugs were stopped since symptoms did not improve after 2 months 
of  therapy.  While  being  worked  up  for  systemic  chemotherapy,  she  was  received  tablets  prednisolone  60mg  daily  (tapered),  and  tablets 
levofloxacin 500mg daily for empirical coverage of bacterial pneumonia. After an initial improvement, her condition rapidly deteriorated and she 
died shortly thereafter. Unfortunately, permission for post-mortem was denied on cultural grounds.  
  
  
Discussion 
 
The clinical presentations of our patients are consistent with established case definitions for IRIS [6,7]. IRIS is an inflammatory disease, the 
consequence of exaggerated dysregulated immune-antigen interactions following HAART-induced immune restoration [1]. During IRIS, occult 
infections may unmask (e.g. case 1 and 2) or pre-existing infections may exacerbate paradoxically, as exemplified in the case with Kaposi’s 
sarcoma, a human herpes virus 8-induced malignancy known to resolve with HAART [8].  
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Profound immunosuppression as reflected in low baseline CD4 cell count was a risk factor for IRIS [1] identified in our patients. The disseminated 
clinical presentation may probably be due to high antigen burden prior to HAART initiation [1], with IRIS promoted by an exuberant immune 
reconstitution [1] evident by excellent immunological and virological response (e.g. viral load dropped by 95% in case 2) to HAART.  
  
To diminish the exuberant inflammatory response and improve recovery, anti-inflammatory drugs such as steroids remain the cornerstone in the 
management of moderate to severe IRIS [9]. Although post-mortem diagnosis was impossible, it  is our view that progressive lung Kaposi’s 
sarcoma, which was initially misdiagnosed as pulmonary tuberculosis, led to the death of our patient. This case emphasizes the need for clinicians 
to be vigilant to the possibility of pulmonary KS in HIV-infected patients presenting with cough and haemopytsis. Unfortunately, pulmonary KS is 
notorious for high fatality, even with systemic chemotherapy [10,11].  
  
  
Conclusion 
 
We have described three cases of disseminated infections following HAART-induced immune reconstitution in HIV-1 infected adult Nigerians. It is 
desirable for future studies to investigate the clinical spectrum and risk factors of IRIS in adult Nigerians.  
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Figures 
 
Figure 1: Multidermatomal herpes zoster in a female with Disseminated infections due to Immune Reconstitution Inflammatory Syndrome after 
Highly Active Antiretroviral Therapy  
 
Figure 2: Disseminated Kaposi’s sarcoma due to Immune Reconstitution Inflammatory Syndromes (IRIS) - multiple papulonodular dark-coloured 
generalised skin lesions with oedema especially involving the face  
  
  
References 
 
1.  Bonham Shuli, Meya David Bohjanen Paul and Boulware David. Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome. 
Biomark Med. 2008;2(4):349-361. This article on PubMed 
 
2.  Shelburne  SA,  Visnegarwala  F,  Darcourt  J,  Graviss  EA,  Giordano  TP,  et  al.  Incidence  and  risk  factors  for  immune  reconstitution 
inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005 Mar 4;19(4):399-406. This article on PubMed 
 
3.  Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type-1 
infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis. 2004 Dec 1;39(11):1709-12. This article on 
PubMed 
 
4.  Park WB, Choe PG, Jo JH, Kim SH, Bang JH, et al. Immune reconstitution inflammatory syndrome in the first year after HAART: influence 
on long-term clinical outcome. AIDS. 2006 Nov 28;20(18):2390-2. This article on PubMed 
 
5.  National  agency  for  control  of  AIDS:  National  HIV/AIDS  Strategic  Framework  (NSF)  2010-15.  2009  publication.  Available  at 
www.naca.gov. Accessed October 1, 2010 
 
6.  International  Network  for  the  Study  of  HIV-  Associated  IRIS  (INSHI).  Consensus  Guidelines  for  General  IRIS.  at 
www.inshi.umn.edc.definitions. Retrieved October 1, 2010 
 
7.  Haddow Lewis, Easterbrook Philippa, Mosam Anisa, Khanyile Nonhlanhla, Parboosing Raveen, Moodley Pravikrishen, Moosa Mohomed-
Yunus. Defining Immune Reconstitution Inflammatory Syndrome: Evaluation of Expert Opinion versus 2 Case Definitions in a South 
African Cohort. Clin Infect Dis. 2009; 49: 1424-32. This article on PubMed 
 
8.  Stebbing  Justin,  Portsmouth  Simon,  Gazzard  Brain.  How  does  HAART  lead  to  the  resolution  of  Kaposi’s  sarcoma?.  J  Antimicrob 
Chemother. 2003; 51:1095-1098. This article on PubMed 
 Page number not for citation purposes  4 
9.  New York State Department of Health AIDS Institute. Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-infected patients. 
Available at www.hivguidelines.org. Accessed October 1 2010 
 
10.  Crane Heidi, Deubner Heike, Huang Jane, Swanson Paul, Harrington Robert. Fatal Kaposi’s sarcoma-associated immune reconstitution 
following HAART initiation.Int J STD AIDS. 2005 Jan;16(1):80-3. This article on PubMed 
 
11.  Leidner  Rom,  Aboulafia  David.  Recrudescent  Kaposi's  sarcoma  after  initiation  of  HAART:  a  manifestation  of  immune  reconstitution 
syndrome. AIDS Patient Care STDS. 2005 Oct;19(10):635-44. This article on PubMed 
 
 
 
 
 
 
 Page number not for citation purposes  5 
 